AstraZeneca’s Covid-19 antibody cocktail cuts the risk of severe disease or death from any cause in patients by half, the company said on Monday.
The drug, AZD7442, had previously shown a significant effect in preventing any symptom of coronavirus.
But trials show a 600mg dose of the drug reduced the risk of developing severe Covid or death from any cause by 50 per cent.
您已阅读14%（373字），剩余86%（2229字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。